Menu
Products and pipeline for amnion-based dissolvable contact lenses include innovative therapeutic lenses under development, targeting ocular surface disorders, enhancing healing, and undergoing clinical trials for broader ophthalmic applications and regulatory approvals.
Diopter announces the expansion of the phase I safety study to treat cornea infection and injury. The first patients were dosed using the proprietary drug-eluting contact lens technology. The initial study data has reported no adverse events from the drug and lens combination. The study has now completed tests on 12 patients and will continue to enroll patients and is scheduled to conclude by the end of Q2 2025.
The market for an effective and convenient treatment for cornea infection and injury includes more than 10 million patients in the US and EU. Current standard of care requires the patient to administer antibiotic eye drops on a frequent basis over several days to treat the ocular infection. The Glint lens will eliminate the need for most patients to use the antibiotic eye drops. Replacing the need for patients to apply eye drops will increase compliance and may lead to better therapeutic outcomes.
Diopter Technologies holds a strong intellectual property foundation. They are inviting investors and collaborators to help reshape the future of ophthalmology and improve the lives of millions of patients globally.